Printer Friendly

HARRIER'S TUMOSTERONE(TM) SHOWN TO KILL CANCER CELLS IN FIRST PHASE OF INDEPENDENT TESTS

 HARRIER'S TUMOSTERONE(TM) SHOWN TO KILL CANCER CELLS
 IN FIRST PHASE OF INDEPENDENT TESTS
 LOS ANGELES, Dec. 3 /PRNewswire/ -- Harrier, Inc. (NASDAQ: HARE) announced today that completed in-vitro studies confirmed the effectiveness of its Tumosterone pharmaceutical against cancer cells.
 Tumosterone is the chemical reproduction of a substance produced naturally in the body which is believed to inhibit the growth of cancerous tumors. The in-vitro studies, performed at the Cancer Therapy and Research Center Institute for Drug Development in San Antonio, Texas, demonstrated the product's cytotoxicity (cancer-killing capability) on several types of tumor cells with varying degrees of potency, and its effect on normal cells, thus indicating a favorable Therapeutic Index.
 Harrier said its Tumosterone drug synthesizes a glycosylated version of the natural substance in order to enhance solubility, reduce side effects and improve administration. These factors, among others, should be clarified upon completion of in-vivo animal tests at the Research Center scheduled in mid-January.
 -0- 12/3/91
 /CONTACT: Kevin DeVito, vice president-U.S. operations of Harrier, 213-376-7721/
 (HARE) CO: Harrier, Inc. ST: California IN: MTC SU:


JT-OS -- NY035 -- 8717 12/03/91 11:25 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 3, 1991
Words:186
Previous Article:THE FUTURE NOW, INC. COMPLETES TARGETED ACQUISITION
Next Article:LOGITECH SHIPS SCANMAN(R) MODEL 256 GRAY SCALE SCANNER WITH PERCEIVE PERSONAL(TM) OCR SOFTWARE
Topics:


Related Articles
HARRIER SPONSORS PHARMACEUTICAL RESEARCH PROJECT AT U. OF MICHIGAN; ENTERS SEPARATE AGREEMENT TO FUND BIOCHEMICAL DEVELOPMENT ACTIVITY
SECOM TIES WITH HARRIER FOR JOINT R AND D OF NEW ANTI-CANCER DRUG
IMMUNOGEN RECEIVES U.S. PATENT ON ITS CYTOTOXIC AGENT, BLOCKED RICIN, AND ITS USE IN CANCER THERAPEUTICS
Cell Genesys Reports Encouraging Clinical Data for First-Generation GVAX(TM) Vaccine for Melanoma.
Calydon: Experimental Drug Could Be Powerful Treatment Against Prostate Cancer.
Clinical Trials Begin for Men With Metastatic Prostate Cancer.
Researchers Report Novel Strategy to Treat Advanced Prostate Cancer Combining CV787 With Taxotere(TM).
Bavarian Nordic and Pharmexa join forces to develop new breast cancer vaccine.
Bavarian Nordic and Pharmexa Join Forces to Develop New Breast Cancer Vaccine; Bavarian Nordic and Pharmexa Will Collaborate On Developing a New...
Pharmexa and Bavarian Nordic Join Forces to Develop New Breast Cancer Vaccine; Pharmexa and Bavarian Nordic will collaborate on developing a new...

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters